Lannett (LCI) Catches Bid Following Phentermine HCl ANDA Approval
Tweet
Share
E-mailGet Alerts LCI Hot Sheet
Join SI Premium – FREE
Lannett (NYSE: LCI) shares have popped higher following reports the U.S. FDA has approved its Abbreviated New Drug Application (ANDA) of Phentermine HCl Capsules, 37.5 mg.
The stock is up nearly 3 percent on the session this afternoon, after being relatively flat all day.
The stock is up nearly 3 percent on the session this afternoon, after being relatively flat all day.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- AC Immune reports early Phase 1 data for NLRP3 inhibitor ACI-19764
- Gossamer Bio raises up to $250M in private placement for PAH drug
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
